LUNG Pulmonx Corp

ProLung, Inc., a medical technology company, develops, markets, and sells precision predictive analytical medical devices specializing in lung cancer in the United States. It offers ProLung system, which consists of various medical grade components comprising a probe, scanner, tower, monitor, and keyboard; and ProLung test kits that assess the risk of malignancy in lung nodules found in the chest by a computed tomography scan, which is used for the early detection of lung cancer. The company was formerly known as Fresh Medical Laboratories, Inc. and changed its name to ProLung, Inc. in April 2017. ProLung, Inc. was founded in 2004 and is headquartered in Salt Lake City, Utah.

$30.40  -0.15 (-0.48%)
As of 12/03/2021 10:29:53 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Medical Devices
Index country:  USA
Country of incorporation:  USA
IPO date:  03/23/2018
Outstanding shares:  36,838,698
Average volume:  427,317
Market cap:   $1,128,369,320
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    745848101
ISIN:        US7458481014
Sedol:      BL72R71
Valuation   (See tab for details)
PE ratio:   -25.63
PB ratio:   5.54
PS ratio:   25.34
Return on equity:   -21.64%
Net income %:   -98.57%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy